The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer

The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer

Anti-estrogens or aromatase inhibitors in combination with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are the current standard of care for estrogen receptor-positive (ER+) Her-2 negative metastatic breast cancer. Although these combination therapies prolong progression-free survival compare...

Full description

Bibliographic Details
Main Authors: Ryan M. Finnegan, Ahmed M. Elshazly, Nipa H. Patel, Liliya Tyutyunyk-Massey, Tammy H. Tran, Vishnu Kumarasamy, Erik S. Knudsen, David A. Gewirtz
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Oncology
Subjects:
cancer
autophagy
senescence
fulvestrant
Palbociclib
ARV-825
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.966441/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.966441/full

Similar Items